Patents by Inventor Julien Valton

Julien Valton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11312782
    Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: April 26, 2022
    Assignee: Pfizer Inc.
    Inventors: Tracy Chia-Chien Kuo, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Ariel Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
  • Publication number: 20220010292
    Abstract: The present invention relates to a method for the generation of compact Transcription Activator-Like Effector Nucleases (TALENs) that can efficiently target and process double-stranded DNA. More specifically, the present invention concerns a method for the creation of TALENs that consist of a single TALE DNA binding domain fused to at least one catalytic domain such that the active entity is composed of a single polypeptide chain for simple and efficient vectorization and does not require dimerization to target a specific single double-stranded DNA target sequence of interest and process DNA nearby the DNA target sequence. The present invention also relates to compact TALENs, vectors, compositions and kits used to implement the method.
    Type: Application
    Filed: September 29, 2021
    Publication date: January 13, 2022
    Applicant: CELLECTIS
    Inventors: Philippe Duchateau, Julien Valton, Claudia Bertonati, Jean-Charles Epinat, George H. Silva, Alexandre Juillerat, Marine Beurdeley
  • Patent number: 11220683
    Abstract: The present invention relates to polypeptides and more particularly to Transcription Activator-Like Effector derived proteins that allow to efficiently target and/or process nucleic acids. Particularly, the present invention reports the characterization of TALE derived proteins that can efficiently target methylated DNA. The present invention more specifically relates to TALE derived proteins that allow activation of methylated promoters responsible for gene silencing.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: January 11, 2022
    Assignee: CELLECTIS
    Inventors: Philippe Duchateau, Julien Valton
  • Patent number: 11198856
    Abstract: The present invention relates to a method for the generation of compact Transcription Activator-Like Effector Nucleases (TALENS) that can efficiently target and process double-stranded DNA. More specifically, the present invention concerns a method for the creation of TALENs that consist of a single TALE DNA binding domain fused to at least one catalytic domain such that the active entity is composed of a single polypeptide chain for simple and efficient vectorization and does not require dimerization to target a specific single double-stranded DNA target sequence of interest and process DNA nearby the DNA target sequence. The present invention also relates to compact TALENs, vectors, compositions and kits used to implement the method.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: December 14, 2021
    Assignee: CELLECTIS
    Inventors: Philippe Duchateau, Julien Valton, Claudia Bertonati, Jean-Charles Epinat, George H. Silva, Alexandre Juillerat, Marine Beurdeley
  • Patent number: 11186824
    Abstract: The present invention relates to methods for developing engineered immune cells such as T-cells for immunotherapy that have a higher potential of persistence and/or engraftment in host organism. IN particular, this method involves an inactivation of at least one gene involved in self/non self recognition, combined with a step of contact with at least one non-endogenous immunosuppressive polypeptide. The invention allows the possibility for a standard and affordable adoptive immunotherapy, whereby the risk of GvH is reduced.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: November 30, 2021
    Assignee: CELLECTIS
    Inventors: Philippe Duchateau, Jean-Pierre Cabaniols, Julien Valton, Laurent Poirot
  • Patent number: 11136566
    Abstract: The present invention relates to new Transcription Activator-Like Effector proteins and more particularly new Transcription Activator-Like Effector Nucleases (TALENs) that can efficiently target and process nucleic acids. The present invention also concerns methods to use these new Transcription Activator-Like Effector proteins. The present invention also relates to vectors, compositions and kits in which Transcription Activator-Like Effector proteins of the present invention are used.
    Type: Grant
    Filed: January 2, 2019
    Date of Patent: October 5, 2021
    Assignee: Cellectis
    Inventors: Philippe Duchateau, Alexandre Juillerat, Julien Valton, Claudia Bertonati, Jean-Charles Epinat, George H. Silva
  • Patent number: 11014989
    Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward CLL1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for immunotherapy for treating cancer, in particular leukemia.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: May 25, 2021
    Assignee: Cellectis
    Inventors: Julianne Smith, Julien Valton, Alexandre Juillerat, Philippe Duchateau, Barbra Johnson Sasu, Arvind Rajpal
  • Publication number: 20210128613
    Abstract: The invention pertains to the field of adoptive cell immunotherapy. It provides with engineered immune cells comprising genetic alteration into genes which are involved into immune functions downregulation, especially in response to environment signals such as nutrients depletion. Such method allows the production of more potent immune cells in the context of tumors' microenvironment.
    Type: Application
    Filed: July 20, 2018
    Publication date: May 6, 2021
    Inventors: Philippe DUCHATEAU, Anne-Sophie GAUTRON, Laurent POIROT, Julien VALTON
  • Patent number: 10894093
    Abstract: The present invention relates to therapeutic cells for immunotherapy to treat patients with cancer. In particular, the inventors develop a method of engineering drug-specific hypersensitive T-cell, which can be depleted in vivo by the administration of said specific drug in case of occurrence of a serious adverse even. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: January 19, 2021
    Assignee: CELLECTIS
    Inventors: Julien Valton, Veronique Zennou, Philippe Duchateau, Laurent Poirot
  • Publication number: 20200407694
    Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) into genetically engineered immune cells to prevent cytokine release syndrome to arise during the course of cell therapy. These exogenous coding sequences are more particularly soluble human polypeptides placed under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.
    Type: Application
    Filed: April 16, 2018
    Publication date: December 31, 2020
    Inventors: Brian BUSSER, Philippe DUCHATEAU, Alexandre JUILLERAT, Laurent POIROT, Julien VALTON, Mohit SACHDEVA
  • Patent number: 10813951
    Abstract: The present invention relates to the use of “off-the-shelf” allogeneic therapeutic cells for immunotherapy in conjunction with chemotherapy to treat patients with cancer. In particular, the inventors develop a method of engineering allogeneic T-cell resistant to chemotherapeutic agents. The therapeutic benefits afforded by this strategy should be enhanced by the synergistic effects between chemotherapy and immunotherapy. In particular, the present invention relates to a method for modifying T-cells by inactivating at least one gene encoding T-cell receptor component and by modifying said T-cells to confer drug resistance. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: October 27, 2020
    Assignee: CELLECTIS
    Inventors: Julien Valton, Philippe Duchateau, David Sourdive
  • Publication number: 20200237823
    Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.
    Type: Application
    Filed: March 9, 2018
    Publication date: July 30, 2020
    Inventors: Brian BUSSER, Philippe DUCHATEAU, Alexandre JUILLERAT, Laurent POIROT, Julien VALTON
  • Publication number: 20200224163
    Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.
    Type: Application
    Filed: October 19, 2017
    Publication date: July 16, 2020
    Inventors: Brian BUSSER, Philippe DUCHATEAU, Alexandre JUILLERAT, Laurent POIROT, Julien VALTON
  • Patent number: 10526406
    Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR), under single-chain or multi-chain forms, the specificity of which, to a desired antigen, is conferred by a VNAR polypeptide derived from monomeric antibodies from cartilaginous fish. Such CARs, which aim to redirect immune cell specificity toward selected undesired malignant cells, are compact and thus particularly adapted to target hollow antigens such as ions channels of efflux pumps present at the surface of drug-resistant cells. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: January 7, 2020
    Assignee: CELLECTIS
    Inventors: Philippe Duchateau, Julien Valton
  • Patent number: 10472396
    Abstract: The present invention concerns new modular base-per-base specific nucleic acid binding domains (MBBBD) derived from newly identified proteins from the bacterial endosymbiont Burkholderia Rhizoxinica and their use for engineering nucleic acid processing enzymes, such as specific endonucleases or transcription activators.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: November 12, 2019
    Assignee: CELLECTIS
    Inventors: Claudia Bertonati, Philippe Duchateau, Alexandre Juillerat, George Silva, Julien Valton
  • Publication number: 20190338273
    Abstract: The present invention relates to polypeptides and more particularly to Transcription Activator-Like Effector derived proteins that allow to efficiently target and/or process nucleic acids. Particularly, the present invention reports the characterization of TALE derived proteins that can efficiently target methylated DNA. The present invention more specifically relates to TALE derived proteins that allow activation of methylated promoters responsible for gene silencing.
    Type: Application
    Filed: April 9, 2019
    Publication date: November 7, 2019
    Applicant: CELLECTIS
    Inventors: Philippe DUCHATEAU, Julien VALTON
  • Publication number: 20190328783
    Abstract: The present invention relates to therapeutic cells for immunotherapy to treat patients with cancer. In particular, the inventors develop a method of engineering prodrug-specific hypersensitive T-cell, which can be depleted in vivo by the administration of said specific prodrug in case of occurrence of a serious adverse event. The invention opens the way to safer and tunable adoptive immunotherapy strategies for treating cancer.
    Type: Application
    Filed: April 13, 2017
    Publication date: October 31, 2019
    Inventors: Julien VALTON, Philippe DUCHATEAU, Laurent POIROT, Barbra Johnsson SASU, Arvind RAJPAL
  • Publication number: 20190316100
    Abstract: The present invention relates to new Transcription Activator-Like Effector proteins and more particularly new Transcription Activator-Like Effector Nucleases (TALENs) that can efficiently target and process nucleic acids. The present invention also concerns methods to use these new Transcription Activator-Like Effector proteins. The present invention also relates to vectors, compositions and kits in which Transcription Activator-Like Effector proteins of the present invention are used.
    Type: Application
    Filed: January 2, 2019
    Publication date: October 17, 2019
    Applicant: CELLECTIS
    Inventors: Philippe Duchateau, Alexandre Juillerat, Julien Valton, Claudia Bertonati, Jean-Charles Epinat, George H. Silva
  • Publication number: 20190290694
    Abstract: The present invention relates to gene editing methods to engineer primary immune cells that are made resistant to proteasome inhibitors, such as Bortezomib, Carfilzomib, Ixazomib, Marizomib, Delanzomib or Oporozomib, for their use in cell immunotherapy in combination with proteasome inhibitor treatments.
    Type: Application
    Filed: December 20, 2017
    Publication date: September 26, 2019
    Inventors: Anne-Sophie GAUTRON, Philippe DUCHATEAU, Laurent POIROT, Julien VALTON
  • Publication number: 20190241669
    Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
    Type: Application
    Filed: April 15, 2019
    Publication date: August 8, 2019
    Inventors: Tracy Chia-Chien KUO, Bijan Andre BOLDAJIPOUR, Javier Fernando CHAPARRO RIGGERS, Philippe DUCHATEAU, Roman Ariel GALETTO, Alexandre JUILLERAT, Thomas Charles PERTEL, Arvind RAJPAL, Barbra Johnson SASU, Cesar Adolfo SOMMER, Julien VALTON, Thomas John VAN BLARCOM